Press Releases Orexo AB OTC Markets

Equities

ORXOY

US68616W1027

Market Closed - OTC Markets Other stock markets 12:46:33 2024-07-10 pm EDT			5-day change	1st Jan Change
2.12 ^USD	0.00%		-1.40%	+40.40%

May. 08	Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024
May. 08	Orexo AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Orexo AB's sustainability work ranked among top 5% by EcoVadis	Jul. 10	AQ
Orexo: invitation to presentation of the Q2 2024 Interim Report	Jul. 08	AQ
Orexo : Presentation	Jun. 25	PU
Orexo : Life Science Investor Forum US, June 20 (Presentation)	Jun. 13	PU
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm	May. 10	AQ
Orexo Q1 2024 Interim Report	May. 08	AQ
Fentanyl awareness day: The synthetic opioid fentanyl increasingly poisons young Americans	May. 07	PU
Orexo : Invitation to presentation of Orexo´s Q1 2024 Interim Report	May. 02	PU
Report from Orexo AB's annual general meeting, 26 April 2024	Apr. 26	AQ
Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US	Apr. 17	AQ
Orexo announces that the condition for early redemption of its existing bonds has been fulfilled	Apr. 02	AQ
Orexo publishes the Annual and Sustainability Report for 2023	Mar. 28	AQ
Correction: Notice of Annual General Meeting of Orexo	Mar. 15	AQ
Notice of Annual General Meeting of Orexo	Mar. 15	AQ
Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds	Mar. 13	AQ
Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds	Mar. 08	AQ
Orexo strengthens its sustainability work by establishing a social financing framework	Mar. 08	AQ
Orexo and Sobi agree to advance feasibility study with AmorphOX	Feb. 12	AQ
Orexo Interim Report Q4 2023, incl. Full Year Report	Feb. 08	AQ
Orexo's OX640 development results to be presented at the 2024 AAAAI Annual Meeting in Washington, DC	Feb. 06	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Orexo AB OTC Markets

Equities

ORXOY

US68616W1027

Press Releases

Filters